KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Net Margin (2016 - 2025)

Historic Net Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 17.96%.

  • Bristol Myers Squibb's Net Margin rose 82300.0% to 17.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.59%, marking a year-over-year increase of 281000.0%. This contributed to the annual value of 18.49% for FY2024, which is 363600.0% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Net Margin stood at 17.96%, which was up 82300.0% from 10.7% recorded in Q2 2025.
  • Bristol Myers Squibb's Net Margin's 5-year high stood at 21.98% during Q1 2025, with a 5-year trough of 100.36% in Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's Net Margin had a median value of 14.33% in 2022 and averaged 8.39%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -1203600bps in 2024, then surged by 1223400bps in 2025.
  • Over the past 5 years, Bristol Myers Squibb's Net Margin (Quarter) stood at 19.79% in 2021, then decreased by -10bps to 17.75% in 2022, then fell by -14bps to 15.35% in 2023, then tumbled by -96bps to 0.62% in 2024, then skyrocketed by 2817bps to 17.96% in 2025.
  • Its Net Margin stands at 17.96% for Q3 2025, versus 10.7% for Q2 2025 and 21.98% for Q1 2025.